Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2020 08:30 ET | Source: Veru Inc.

Veru Extends Agreement with Roman for Veru’s Premature Ejaculation Treatment Product

-- Three-Year Multi-Million Unit Extension Agreement – -- Roman Swipes Seeing Rapid Growth through Leading Men’s Digital Health Clinic -- MIAMI, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Veru Inc....
August 13, 2020 06:30 ET | Source: Veru Inc.

Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

--Received Agreement and Positive Input from FDA on Phase 3 Pivotal Clinical Trial Design for VERU-111; Phase 3 Trial Expected to Commence in Q1 2021-- --VERU-111 Phase 1b Clinical Trial...
August 04, 2020 08:30 ET | Source: Veru Inc.

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

--VERU-111 significantly reduced key cytokines involved in Acute Respiratory Distress Syndrome in COVID-19 in a toxic shock model-- --VERU-111’s ability to disrupt microtubules has potential for...
July 30, 2020 08:30 ET | Source: Veru Inc.

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

MIAMI, July 30, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
July 27, 2020 08:30 ET | Source: Veru Inc.

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

MIAMI, July 27, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
July 23, 2020 08:30 ET | Source: Veru Inc.

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

MIAMI, July 23, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
June 29, 2020 08:30 ET | Source: Veru Inc.

Veru Inc. Added to the Russell 2000 and 3000 Indices

MIAMI, June 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
June 19, 2020 08:30 ET | Source: Veru Inc.

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

MIAMI, June 19, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
May 26, 2020 08:30 ET | Source: Veru Inc.

Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd

MIAMI, May 26, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer,...
May 13, 2020 06:30 ET | Source: Veru Inc.

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

--Strong Clinical Progress in Advanced Prostate Cancer: VERU-111 Demonstrates Safety and Evidence of Antitumor Activity with Durable PSA Declines and Tumor Regression in Phase 1b Study; Phase 2 Study...